The more cautious voices point to Hims’s high P/E ratio and recent volatility, warning that the stock could cool off after its sharp run-up. That said, a few analysts are still pretty optimistic. They ...

University of Florida researchers said a new study could lead to a universal cancer shot, while digital health earnings ...

If you suffered losses exceeding $50,000 in Hims between April 29, 2025 and June 22, 2025 and would like to discuss your ...

Analysts have provided Laboratory Corp with 8 ratings, resulting in a consensus rating of Neutral. The average one-year price target stands at $276.5, suggesting a potential 9.69% upside.

Kodiak Robotics, Inc. ("Kodiak"), a leading provider of AI-powered autonomous vehicle technology, today announced it has ...

HIMS accelerates global growth with ZAVA buyout, Canadian launch, and soaring EPS estimates pointing to 177.8% upside.

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Hims & Hers Health, Inc. (NYSE: HIMS) between April 29, 2025 and June 23, 2025, both dates inclusive (the ...